However, growing evidence suggests that TP53 concurrently contributes to the regulation of tumor immune response [2,3,4,5,6]; a significant activation of inflammatory and innate immune pathways in CRC caused by TP53 mutation have already been found [7]. This evidence concerns the gene TP53 and colorectal carcinoma.